Ibrutinib
Imbruvica (ibrutinib) is an oral prescription medication that acts as a kinase inhibitor to help treat certain blood cancers. Available as tablets (140mg, 230mg, 420mg, 560mg), capsules (70mg, 140mg), and suspension (70mg/mL), it's manufactured by Pharmacyclics LLC. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Imbruvica (ibrutinib) is an oral prescription medication that acts as a kinase inhibitor to help treat certain blood cancers. Available as tablets (140mg, 230mg, 420mg, 560mg), capsules (70mg, 140mg), and suspension (70mg/mL), it's manufactured by Pharmacyclics LLC. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Ibrutinib", "mediaType": "text/html", "description": " Access the FDA dataset for Ibrutinib — ANDA 205552 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205552" } ] |
| identifier | ANDA205552 |
| issued | 2016-09-16 |
| keyword |
[ "drug-safety", "fda", "health-care", "pharmaceuticals", "prescription-drugs" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Ibrutinib |
